BioSpace News Archive

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced that The University of Tennessee Medical Center’s Cancer Institute has joined Caris’ Precision Oncology Alliance™.

Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced the close of a $112 million Series B financing.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF) today announced it will be participating at the 2022 North American Spine Society (“NASS”) Annual Meeting, October 12-October 15, 2022 at McCormick Place – West Building in Chicago, Illinois at Booth #4604.

Ginkgo Bioworks today announced a collaboration with Merck to engineer up to four enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient (API) manufacturing efforts.

Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, announced the dosing of the first participant in a Phase 1/2a clinical trial evaluating the organization’s Anti-HIV DuoCAR-T cell therapy.

More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation’s leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services.

Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx ® -Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting.

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development.

Sonendo , Inc. today announced its second annual EndoCon , a nationally recognized endodontic conference focused on innovation.

BridgeBio Pharma, Inc., (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in its Phase 1/2 clinical trial of BBP-398.